Report: Market Share Of Orphan Drugs Could Top 20 Percent Of Global Market By 2022 03/04/2017 by Intellectual Property Watch Leave a Comment A new industry report shows that the average prices for orphan drugs are increasing and are projected to comprise more than 20 percent of the patented pharmaceutical sales market by 2022.
France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment 31/03/2017 by Intellectual Property Watch 2 Comments The French Ministry of Social Affairs and Health announced today that the ministry has negotiated with pharmaceutical company Gilead to bring down the prices of hepatitis C medicines.
NGOs Detail Changes For Public Health In RCEP Asian Trade Pact 31/03/2017 by Catherine Saez, Intellectual Property Watch 1 Comment Concerns continue to grow among civil society about provisions in a major trade agreement in the Asian region. Of specific worry is the intellectual property chapter containing in particular a data exclusivity clause, and the linkage between the investment chapter and the IP chapter.
Funding Injection For New Antibiotics: The CARB-X Transatlantic Partnership 30/03/2017 by Kim Treanor for Intellectual Property Watch 1 Comment A partnership of government agencies and organisations in the United States and United Kingdom have announced an investment of up to US$48 million into the development of new antibiotics and products to fight antibiotic resistant bacteria, with the aim of having two new antibiotics in human trials in the next five years.
17 Civil Society Groups Urge EU To Support WHO Resolution On Cancer 30/03/2017 by Intellectual Property Watch 1 Comment A range of civil society organisations today issued a letter to European Union leadership urging support for a World Health Organization resolution that mandates a feasibility study on a fund for cancer research and development that delinks R&D costs from the price of health technologies.
WHO Flu Framework Looks At Virus Genetic Information Sharing, Private Sector Contribution 28/03/2017 by Catherine Saez, Intellectual Property Watch 2 Comments How to deal with genetic information rather than physical samples of pandemic influenza virus continues to be discussed at the World Health Organization. For the moment, only physical samples are part of a framework of access and benefit sharing set up and run by the WHO. This week, the framework advisory group is meeting and according to sources, suggested steps to establish guidance on how to address virus genetic information will be shared by the WHO during the meeting.
Civil Society From 17 European Countries File Patent Opposition On Key Hepatitis C Drug 27/03/2017 by Intellectual Property Watch 2 Comments Public health group Médecins Sans Frontières (MSF) announced today that it has joined civil society organisations from 17 countries in Europe in filing a patent challenge at the European Patent Office to Gilead’s patent on sofosbuvir, an important treatment for hepatitis C.
Situation With IP Rights In Russia Continues To Deteriorate 27/03/2017 by Eugene Gerden for Intellectual Property Watch Leave a Comment The situation with IP rights in Russia is steadily deteriorating, which is mainly due to the recently imposed restrictions for foreign biopharmaceutical companies to participate in public procurement procedures in Russia, the encouragement of parallel imports, as well as the increased consumption of pirated software, according to recent statements of the Russian Ministry of Industry and Trade and local analysts in the field of IP protection.
Medicines Patent Pool Sublicenses New Antibiotic Candidate To TB Alliance For Development 24/03/2017 by Intellectual Property Watch 2 Comments TB Alliance and the Medicines Patent Pool announced today a licensing agreement for the development of sutezolid, a new antibiotic drug candidate which may be used to treat tuberculosis.
What To Watch Out For In The EU-Mercosur FTA Negotiations: Consequences For Access To Medicines 22/03/2017 by Intellectual Property Watch 6 Comments As negotiations take place this week, an evaluation of the impact of one of the TRIPS-plus measures of the Mercosur/EU FTA on the prices of medicines in Brazil has been released. Based on the draft of the agreement, by their calculations, an additional USD 444 million would be necessary to be spent by the public health system for the purchase of six medicines alone, write Marcela Fogaça Vieira and Gabriela Costa Chaves.